Skip to main content
Oncotarget logoLink to Oncotarget
. 2020 Apr 21;11(16):1474–1477. doi: 10.18632/oncotarget.27561

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

Lihui Qu 1,2,3,4,#, Yingying Lu 1,2,3,4,#, Meike Ying 1,2,3,4, Bingjue Li 1,2,3,4, Chunhua Weng 1,2,3,4, Zhoutao Xie 1,2,3,4, Ludan Liang 1,2,3,4, Chuan Lin 1,2,3,4, Xian Yang 1,2,3,4, Shi Feng 1,2,3,4, Yucheng Wang 1,2,3,4, Xiujin Shen 1,2,3,4, Qin Zhou 1,2,3,4, Ying Chen 1,2,3,4, Zhimin Chen 1,2,3,4, Jianyong Wu 1,2,3,4, Weiqiang Lin 1,2,3,4,9, Yi Shen 8, Jing Qin 5,7, Hang Xu 5, Feng Xu 5,7, Junwen Wang 6,8,, Jianghua Chen 1,2,3,4,, Hong Jiang 1,2,3,4,, Hongfeng Huang 1,2,3,4,
PMCID: PMC7185064  PMID: 32363004

This article has been corrected: In Figures 1, 2, 3 and 4, the word ‘mouth’ was mistakenly used instead of ‘month’. The corrected Figures are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 1. FK506 dose adjusted concentration related to CYP3A5 genotype.

Figure 1

FK506 blood concentrations A., FK506 standardized dose B., and dose normalized FK506 concentration C., of CYP3A5* GG recipients and CYP3A5* AA/AG recipients at 7th day, 1st month, 3rd month, 6th month and 12th month after the kidney transplantation. NS: not significant, **: p < 0.01, ****: p < 0.0001. Error bars in graphs indicates SEM.

Figure 2. CsA dose adjusted concentration related to CYP3A5 genotype.

Figure 2

CsA blood concentrations A., CsA standardized dose B. and dose normalized CsA concentration C. of CYP3A5* GG recipients and CYP3A5* AA/AG recipients at 7th day, 1st month, 3rd month, 6th month and 12th month after the kidney transplantation. NS: not significant. Error bars in graphs indicates SEM.

Figure 3. Clinical parameters of liver and kidney injury related to CYP3A5 genotype and different immunosuppressors.

Figure 3

Clinical parameters of kidney function, Scr A., BUN B. and liver injury, ALT C., AST D., for each recipient was measured in 7 day, 1st month, 3rd month, 6th month and 12th month after the kidney transplantation. NS: not significant. Error bars in graphs indicates SEM.

Figure 4. Costs of patients related to CYP3A5 genotype and different immunosuppressors.

Figure 4

Participants’ cost of immunosuppressive agents of different CYP3A5 genotypes. NS: not significant, *: p < 0.05, **: p < 0.01, ****: p < 0.0001, Error bars in graphs indicates SEM.

Original article: Oncotarget. 2017; 8:81285–81294. 81285-81294. https://doi.org/10.18632/oncotarget.18150


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES